


Patent claims

1. A compound of the formula

5



in which

10 R¹ denotes 5- to 10-membered heteroaryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of oxo, halogen, carbamoyl, cyano, hydroxyl, (C₁-C₆-alkyl)carbonyl, trifluoromethyl, trifluoromethoxy, nitro, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

15 where

 R⁵ and R⁶ independently of one another denote for C₁-C₆-alkyl or
20 R⁵ and R⁶, together with the nitrogen atom to which they are bonded,
 denote a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

25 R² denotes C₁-C₆-alkyl or C₃-C₄-cycloalkyl,

 R³ denotes methyl,

 A denotes oxygen or NH,

and

5 R⁴ denotes C₆-C₁₀-aryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of halogen, formyl, carboxyl, carbamoyl, cyano, hydroxyl, trifluoromethyl, trifluoromethoxy, nitro, C₁-C₆-alkyl, C₁-C₆-alkoxy, 1,3-dioxa-propane-1,3-diyl, C₁-C₆-alkylthio and -NR⁷R⁸,

in which

10

R⁷ and R⁸ independently of one another denote hydrogen, C₁-C₆-alkyl or C₁-C₆-alkylcarbonyl,

and their salts, solvates and/or solvates of the salts.

15

2. A compound as claimed in claim 1, where

20

R¹ denotes 5- to 10-membered heteroaryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of oxo, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

where

25

R⁵ and R⁶ independently of one another denote C₁-C₆-alkyl or

R⁵ and R⁶, together with the nitrogen atom to which they are bonded, form a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

30

R² denotes C₁-C₆-alkyl,

R³ denotes methyl,

A denotes oxygen or NH,

5 and

R⁴ denotes phenyl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of halogen, C₁-C₆-alkyl and C₁-C₆-alkoxy,

10

and their salts, solvates and/or solvates of the salts.

3. A compound as claimed in claim 1 and 2, where

15

R¹ denotes thienyl, furyl, thiazolyl or pyridyl, which in each case can be substituted by up to 2 substituents selected independently of one another from the group consisting of oxo, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

20

where

R⁵ and R⁶ independently of one another denote C₁-C₆-alkyl or

25

R⁵ and R⁶, together with the nitrogen atom to which they are bonded, form a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

R² denotes C₁-C₆-alkyl,

30


R³ denotes methyl,

A denotes oxygen or NH,

R⁴ denotes phenyl, which is substituted by up to 3 C₁-C₆-alkoxy radicals,

5 and their salts, solvates and/or solvates of the salts.

4. A process for the preparation of compounds as claimed in claim 1,
characterized in that compounds of the general formula




10

in which

R¹, R² and R³ have the meanings indicated in claim 1,

15

are reacted with compounds of the formula



20

in which

R⁴ and A have the meanings indicated in claim 1,

to give compounds of the formula (I) and these are optionally reacted with the appropriate (i) solvents and/or (ii) bases or acids to give their solvates, salts and/or solvates of the salts.

- 5 5. A compound as claimed in one of claims 1 to 3 for the treatment and/or prophylaxis of diseases.
- 10 6. A medicament containing at least one of the compounds as claimed in one of claims 1 to 3 and at least one pharmaceutically tolerable, essentially nontoxic vehicle or excipient.
- 15 7. The use of the compounds as claimed in one of claims 1 to 3 for the production of a medicament for the treatment and/or prophylaxis of neurodegenerative disorders.
- 20 8. The use of the compounds as claimed in one of claims 1 to 3 for the production of a medicament for the treatment and/or prophylaxis of cancer, neurodegenerative disorders and psychiatric disorders.
- 25 9. The use as claimed in claim 7, where the neurodegenerative disorder is Parkinson's disease.
10. 10. The use as claimed in claim 8, where the psychiatric disorder is schizophrenia.
- 30 11. A process for the control of cancer, neurodegenerative disorders and psychiatric disorders in a human or animal by administration of an efficacious amount of the compounds from claims 1 to 3.
12. 12. The process as claimed in claim 11, where the neurodegenerative disorder is Parkinson's disease.

13. The process as claimed in claim 11, where the psychiatric disorder is schizophrenia.